TESARO announces positive top-line results from Quadra trial of Zejula

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Recurrent:

  • NOVA: Monotherapy phase III trial for patients with platinum sensitive, recurrent ovarian cancer, regardless of biomarker status (complete; patients being followed for overall survival)

  • AVANOVA: Combination phase II trial with bevacizumab for patients with recurrent ovarian cancer; anticipate data to be available in 2H 2018 to support data submission for a meeting held in 2019

Platinum-Resistant:

  • TOPACIO: Combination phase II trial with anti-PD-1 for patients with platinum-resistant ovarian cancer or triple negative breast cancer (abstracts accepted for presentation at ASCO)

YOU MAY BE INTERESTED IN

In the days leading up to the 2021 American Society of Clinical Oncology annual meeting, The Cancer Letter published a piece focused on Axel Grothey’s unethical sexual relationships with women he mentored while at Mayo Clinic. While this news was met by some as shocking, science tells us it is anything but.

Login